Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the expected launch of triple reuptake inhibitors in 2009 will drive the market for treating major depression as these therapies will command a premium price due to their novel mechanisms of action, better efficacy, and improved side effect profile.

The new Pharmacor report entitled Major Depression finds that despite generic competition in this mature and highly-fragmented market, drug developers continue to have an avid interest in antidepressants as more than 45 compounds are in clinical development for the treatment of major depression. Developers of triple reuptake inhibitors -- which inhibit the reuptake of serotonin, norepinephrine, and dopamine -- are hopeful that these agents will offer advantages in tolerability and efficacy over currently popular drug classes such as serotonin and norepinephrine inhibitors and selective serotonin reuptake inhibitors.

"GlaxoSmithKline, Merck, and Sepracor all have triple reuptake inhibitor compounds currently in clinical development," said Natalie Taylor, analyst at Decision Resources. "In order to establish a presence in this market, novel antidepressant drugs will need to be clearly differentiated from the large number of generic first-line therapies, and they will need to be aggressively marketed to primary care physicians if they are to attain sales that approach the blockbuster status enjoyed by Pfizer's Zoloft (sertraline) and Wyeth's Effexor (venlafaxine)."

About Major Depression

In 2004, the number of diagnosed cases of major depression in the United States, Western Europe, and Japan was approximately 21 million.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs currently on the market and in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Indianapolis's Unregulated Hospital Market Continues Its Building Boom, According To HealthLeaders-InterStudy

View Now